Study of patients diagnosed with advanced HIV in the HAART era - OMEGA Cohort

International Journal of STD and AIDS

Volumn 16, Issue 3, 2005, Pages 252-255

  Santos, Jesús ^a   Palacios, R ^a   Ruiz, J ^a   Gonzalez M ^a   Marquez M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Advanced HIV infection; Cohort study; HAART; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ILLICIT DRUG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HOMOSEXUALITY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTRAVENOUS DRUG ABUSE; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 16344381509     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462053420167     Document Type: Article

References (25)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeciency virus infection. N Engl J Med 1998;338:853-60
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30
3. Murphy EL, Collier AC, Kalish LA. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26
4. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77
5. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29
6. Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. AIDS 1999;13:2317-30
7. López de Munain J, Cámara MM, Santamaría JM, Zubero Z, Baraia-Etxaburu J, Muñoz J. Características clinicoepidemiológicas de los nuevos diagnósticos de infección por el virus de la inmunodeficiencia humana. Med Clin (Barc) 2001;117:654-6
8. Castilla V, Alberdi JC, Barros C, Gómez J, Gaspar G, Sanz J. Cohorte multicéntrica de pacientes con infección VIH de la corona metropolitana sur-este de Madrid (COMESEM): fundamentos, organización y resultados iniciales. Rev Clin Esp 2003;203:170-7
9. Santos J, Palacios R, Gutiérrez M, et al. HIV Infection in the era of highly active antiretroviral therapy. The Malaga Study. Int J STD AIDS 2004;15:594-6
10. Hocking JS, Rodger AJ, Rhodes DG, et al. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis - characteristics of individuals. Int J STD AIDS 2000;11:503-8
11. Klein D, Hurley LB, Merrill D, Quesenberry CP. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003;32:143-52
12. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-20
13. Carr A. HIV protease inhibitor-induced lipodystrophy syndrome. AIDS Rev 1999;1:29-36
14. Expert Committee on the Diagnosis Classification of Diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998;21:S5-19
15. National Cholesterol Education Program. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;10:299-313
16. Joint National Committee. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46
17. Girardi E, Sampaolesi A, Gentile M, et al. Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:71-6
18. Hocking JS, Rodger AJ, Rhodes DG, et al. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis - characteristics of individuals. Int J STD AIDS 2000;11:503-8
19. Castilla J, Sobrino P, de la Fuente L, et al. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002;16:1945-51
20. Dybul M, Bolan R, Condoluci D, et al. Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus, by sex and race, in urban settings. J Infect Dis 2002;185:1818-21
21. Lederman M, McKinnis R, Kelleher D, et al. Cellular restoration in HIV-infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000;14:2635-42
22. Connick E, Lederman M, Kotzin B, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000;81:358-63
23. Barreiro P, Soriano V, Casas E, González-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002;16:245-9
24. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30
25. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med 2003;348:679-80